Ehrke M J, Tomazic V, Ryoyama K, Cohen S A, Mihich E
Int J Immunopharmacol. 1983;5(1):43-8. doi: 10.1016/0192-0561(83)90070-x.
The immunomodulating capabilities of the anti-neoplastic agent, Adriamycin, were investigated. The day of Adriamycin administration to mice was varied from -15 to -1, day 0 being when mice were either immunized or sacrificed and their spleen cells sensitized in culture. Humoral and cellular immune responses against allogeneic or xenogeneic cellular antigens in mice and in culture, as well as phagocytic and ADCC activities were evaluated using spleen cell populations. The cellular responses and phagocytic activities were affected in a cyclical manner with time after Adriamycin's administration. Peaks of increased activity were seen subsequent to day -5 and day -11, administration and low activities following day -1, -3 and day -7, -9 administration. The humoral responses were not affected in a biphasic manner but single peaks of increased activity were seen which corresponded to the times of low cellular cytolytic and phagocytic activities. The ADCC was independent of time of Adriamycin administration. The significance of these findings to the design of therapeutic protocols is discussed.
研究了抗肿瘤药物阿霉素的免疫调节能力。给小鼠注射阿霉素的日期在-15天至-1天之间变化,第0天是小鼠进行免疫或处死并在培养中使脾细胞致敏的日子。使用脾细胞群体评估了小鼠体内和培养物中针对同种异体或异种细胞抗原的体液免疫和细胞免疫反应,以及吞噬和ADCC活性。阿霉素给药后,细胞反应和吞噬活性随时间呈周期性变化。在给药后第-5天和第-11天之后出现活性增加的峰值,而在给药后第-1天、-3天以及第-7天、-9天之后活性较低。体液反应没有受到双相影响,而是出现了活性增加的单峰,这与细胞溶解和吞噬活性较低的时间相对应。ADCC与阿霉素给药时间无关。讨论了这些发现对治疗方案设计的意义。